Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 32, Issue 1, 2017, Pages 960-967

  Tzvetkov, Nikolay T ^a   Antonov, Liudmil ^b  

^a NTZ Lab Ltd   (Bulgaria)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Bulgaria)

Author keywords

Alzheimer s disease; free energy calculations; iron chelators; MAO inhibitors; Parkinson s disease

Indexed keywords

INDAZOLE 5 CARBOXAMIDE INHIBITOR; INDAZOLE DERIVATIVE; MONOAMINE OXIDASE B INHIBITOR; NTZ 1006; NTZ 1032; NTZ 1441; SAFINAMIDE; SELEGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); IRON; MONOAMINE OXIDASE INHIBITOR;

ARTICLE; BRAIN; DRUG BINDING; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; IC50; IRON CHELATION; MOLECULAR DOCKING; MOLECULAR MODEL; PARKINSON DISEASE; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

BINDING SITES; BRAIN; HUMANS; INDAZOLES; IRON; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85025067496     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756366.2017.1344980     Document Type: Article

References (31)

1. Santos MA, Chand K, Chaves S., Recent progress in multifunctional metal chelators as potential drugs for Alzheimer´s disease. Coord Chem Rev 2016;327–328:287–303.
2. Meredith GE, Totterdell S, Beales M, et al. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp Neurol 2009;219:334–40.
3. Belaidi AA, Bush AI., Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease:targets for therapeutics. J Neurochem 2016;139(Suppl I):179–97.
4. Dunkel P, Chai CL, Sperlágh B, et al. Clinical utility of neuroprotective agents in neurodegenerative disease:current status of drug development for Alzhemer’s, Parkinson’s and Huntington´s diseases, and amyotrophic lateral sclerosis. Exp Opin Investig Drugs 2012;21:1267–308.
5. Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol 2012;25:433–47.
6. Tong J, Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase proteins in human brain:implication for brain imaging studies. J Cereb Blood Flow Metab 2013;33:863–71.
7. Shih JC, Chen K, Ridd MJ., Monoamine oxidase:from genes to behavior. Annu Rev Neurosci 1999;22:197–217.
8. Nicotra A, Pierucci F, Parvez H, et al. Monoamine oxidase expression during development and aging. NeuroToxicol 2004;25:155–65.
9. Youdim MBH, Lavie I., Selective MAO-A and MAO-B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson’s disease. Life Sci 1994;55:2077–82.
10. Wang Y, Wang H, Chen H-Z., AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer’s disease. Curr Neuropharmacol 2016;14:364–75.
11. Fowler JS, Logan J, Volkow ND, et al. Evidence that formulations of the selective MAO-B inhibitor selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 2015;40:650–7.
12. Kumar B, Sheetal Mantha AK, et al. Recent developments on the structure-activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Adv 2016;6:42660–83.
13. Fabbri M, Rosa MM, Abreu D, et al. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegener Dis Manag 2015;5:481–96.
14. Tzvetkov NT., Substituted indazole or indole derivatives as in vitro MAO-B inhibitors. Patent WO2014/107771, 2014.
15. Tzvetkov NT, Hinz S, Gastreich M, et al. Indazole- and indole-5-carboxamides:selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. J Med Chem 2014;57:6679–703.
16. Tzvetkov NT, Stammler H-G, Neumann B, et al. Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors. Eur J Med Chem 2017;127:470–92.
17. Carradori S, Silvestri R., New frontiers in selective human MAO-B inhibitors. J Med Chem 2015;58:6717–32.
18. SeeSAR v.5.5, BioSolveIT GmbH, Sankt Augustin, Germany 2017. Available from:http://www.biosolveit.de/SeeSAR.
19. LeadIT v.2.1.9, BiosolveIT GmbH, Sankt Augustin, Germany 2016. Available from:http://www.biosolveit.de/LeadIT.
20. Binda C, Wang J, Pisani I, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors:safinamide and coumarin analogs. J Med Chem 2007;50:5848–52.
21. Schneider N, Hindle S, Lange G, et al. Substantial improvements in large-scale redocking and screening using the novel HYDE scoring function. J Comput Aided Mol Des 2012;26:701–23.
22. Schärfer C, Schulz-Gasch T, Ehrlich HC, et al. Torsion angle preferences in druglike chemical space:a comprehensive guide. J Med Chem 2013;56:2016–28.
23. Di L, Kerns EH, Fan K, et al. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003;38:223–32.
24. i) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099–108.
25. Clark DE. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 1999;88:807–14.
26. Wager TT, Hou X, Verhoest PR, Villalobos A., Moving beyond rules:the development of a central nervous system multiparameter optimization (CNS MPO) approach to enhance alignment of drug-like properties. ACS Chem Neurosci 2010;1:435–49.
27. Hitchcock SA, Pennington LD., Structure-brain exposure relationships. J Med Chem 2006;49:7559–83.
28. Ahsan MJ, Samy JG, Khalilullah H, et al. Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents. Bioorg Med Chem Lett 2011;21:7246–50.
29. Abad-Zapatero C., Ligand efficiency indices for effective drug discovery. Expert Opin Drug Discov 2007;2:469–88.
30. Vilar S, Chakrabarti M, Costanzi S., Prediction of passive blood-brain partitioning:straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model 2010;28:899–903.
31. Johnson TW, Dress KR, Edwards M., Using the Golden Triangle to optimize clearance and oral absorption. Bioorg Med Chem Lett 2009;19:5560–4.